Connect with us

Technology

Stoneridge Reports Second Quarter 2026 Results

Published

on

Strengthening Demand & Expense Control Underpin 2Q Performance

NOVI, Mich., Aug. 5, 2026 /PRNewswire/ — Stoneridge, Inc. (NYSE: SRI) today announced financial results for the second quarter ended June 30, 2026.

2026 Second Quarter Highlights:

Sales growth of 15.1% YoY to $181.4 millionRecord quarterly MirrorEye revenue of ~$37 million (+39% YoY)Record quarterly revenue for Stoneridge Brazil of $20.5 millionNet loss from continuing operations of $5.3 million, or $0.19 per share; improved from a net loss of $11.1 million, or $0.40 per share, in the prior yearAdjusted EBITDA of $5.5 million; best quarterly performance in 24 monthsReaffirming 2026 guidance ranges

“Our second quarter performance reflects disciplined execution of our strategy as we improve our cost structure and focus our resources on the opportunities that will drive long-term value,” said Natalia Noblet, president and chief executive officer. “In Brazil, our strategic shift toward high-value OEM programs continues to position the business for more sustainable, profitable growth. With strong execution across the business, we remain confident in our strategy and are reaffirming our full-year guidance for 2026.”

The exhibits attached hereto provide reconciliation details on normalizing adjustments of non-GAAP financial measures used in this press release.

Second Quarter Results & Commentary

(in millions, except percentages and per share data)

Results

Three Months Ended June 30,
2026

%

2026

2025

Change

Net Sales

$ 181.4

$ 157.5

15.1 %

Gross Profit

36.8

36.3

1.3 %

Gross Margin %

20.3 %

23.1 %

277 bps

Income (loss) from Operations

(1.2)

(4.2)

71.7 %

Income (loss) before taxes from continuing operations

(2.7)

(9.6)

71.6 %

Provision for income taxes from continuing operations

2.6

1.5

65.6 %

Net Income (loss) from continuing operations

(5.3)

(11.1)

52.6 %

Net Income (loss) per diluted common share from
continuing operations

(0.19)

(0.40)

53.4 %

Weighted-average common shares outstanding

28.2

27.8

1.6 %

Adjusted consolidated EBITDA

$   5.5

$   0.8

578.5 %

Adjusted consolidated EBITDA %

3.0 %

0.5 %

251 bps

Consolidated net sales from continuing operations of $181.4 million increased 15.1% YoY. On a core basis, excluding favorable currency translation of $4.4 million and Mexico Manufacturing Agreement revenue of $7.1 million related to the sale of the Control Devices business, revenue improved 7.8% YoY.  The North American commercial vehicle market and Stoneridge Brazil were the primary contributors to second quarter growth.

Gross margin decreased 277 basis points to 20.3% from 23.1% in the second quarter of 2025 as cost leverage on higher sales and benefits from targeted expense control initiatives were more than offset by a combination of higher material costs, stemming from unfavorable currency, strategic inventory-related actions and adverse product mix following the completion of a European regulatory retrofit campaign.

Consolidated net loss from continuing operations totaled $(5.3) million, or $(0.19) per share, compared to a net loss of $(11.1) million, or $(0.40) per share, for the quarter ended June 30, 2025.

Non-GAAP adjusted EBITDA totaled $5.5 million, or 3.0% of sales, compared to $0.8 million, or 0.5% of sales, in the year ago period.

Second Quarter GAAP Segment Results & Commentary

(in millions, except percentages and per share data)

Revenue

Three Months Ended June 30, 2026

Constant

%

Currency

2026

2025

Change

vs. 2025

Electronics

$     160.9

$     142.7

12.8 %

11.0 %

Stoneridge Brazil

20.5

14.9

37.6 %

25.7 %

Consolidated Net Sales

181.4

157.5

15.1 %

12.4 %

 

(in millions, except percentages and per share data)

Operating Income

Three Months Ended June 30, 2026

%

2026

2025

Change

Electronics

$   4.9

$   2.7

77.2 %

% of segment sales

3.0 %

1.9 %

110 bps

Stoneridge Brazil

2.6

1.0

165.8 %

% of segment sales

12.6 %

6.5 %

607 bps

Corporate

(8.6)

(7.9)

(9.0) %

Consolidated Operating Income

$  (1.2)

$  (4.2)

71.7 %

% of consolidated net sales

(0.7) %

(2.7) %

201 bps

Electronics second quarter sales of $160.9 million increased by $18.2 million, or 12.8%, relative to the second quarter of 2025. Excluding a favorable foreign currency translation impact of $2.6 million and Mexico Manufacturing Agreement revenue related to the sale of the Control Devices business, revenue improved 6.0% YoY. Revenue growth against the second quarter of 2025 was primarily driven by the North American commercial vehicle market. Second quarter adjusted operating margin increased by 12 basis points YoY to 3.0% as the benefits of a higher revenue base and implemented cost initiatives more than offset the cumulative impacts of unfavorable mix, currency and strategic inventory-related actions.

Stoneridge Brazil second quarter sales of $20.5 million increased by $5.6 million, or 37.6%. Excluding a favorable foreign currency translation impact of $1.8 million, sales improved by 25.7%. Higher OEM sales were the primary driver of growth during the quarter. Second quarter adjusted operating income of $2.3 million, or 11.2% of sales, increased 135.5%, or 464 basis points, compared to the second quarter of 2025 as higher sales volume more than offset increased SG&A expense.

Cash and Debt Balances

As of June 30, 2026, cash and cash equivalents totaled $71.5 million with total debt of $151.1 million, resulting in net debt of $79.6 million. The $38.5 million decrease in net debt compared to December 31, 2025 reflects the deployment of proceeds from the sale of the Control Devices business in January and tighter control of working capital during the first half of the year. The Company’s Credit Facility is due to mature on July 1, 2027.  The company expects to refinance the credit facility, and is currently engaged in a global refinancing process.

2026 Outlook & Management Commentary

The Company is reaffirming the 2026 guidance ranges that were most recently updated in May. “We are encouraged by our progress in the second quarter, and believe initiatives to generate operational efficiencies and enhance profitability are beginning to materialize,” said Noblet. “We are also seeing promising signs across the European and North American commercial vehicle markets, which should support growth over the balance 2026.  However, we believe it prudent to balance these positives against ongoing macroeconomic and geopolitical uncertainty. We continue to focus on material cost reductions, quality improvements as well as inflationary cost recovery, and remain committed to executing our long-term strategic plan as we navigate the challenging external environment.”

2026 FULL YEAR
GUIDANCE

(in millions, except percentages and per
share data)

2026

Current

Revenue ($M)

$645

$670

Adj. Gross Margin

21.5 %

22.0 %

Adj. Operating Margin

— %

0.5 %

Adj. EBITDA ($M)

$20

$25

%

3.1 %

3.7 %

The Company has not provided a reconciliation of its full-year 2026 guidance for adjusted gross margin, adjusted operating margin, and adjusted EBITDA (or adjusted EBITDA margin) to the most directly comparable GAAP financial measures because the Company is unable to provide such reconciliations without unreasonable effort. This is due to the inherent difficulty of forecasting with the required precision the timing and amount of various items that have not yet occurred, are out of the Company’s control, or cannot be reasonably predicted. For the same reasons, the Company is unable to address the probable significance of the unavailable reconciling information, which could be material to future results calculated in accordance with GAAP. The Company’s actual results calculated in accordance with GAAP may vary materially from these non-GAAP financial measures presented herein.

Conference Call on the Web
A live Internet broadcast of Stoneridge’s conference call regarding 2026 second quarter results can be accessed at 8:00 a.m. Eastern Time on Thursday, August 6, 2026, at www.stoneridge.com, which will also offer a webcast replay.

About Stoneridge, Inc.
Stoneridge, Inc., headquartered in Novi, Michigan, is a global supplier of safe and efficient electronic systems and technologies. Our systems and products power vehicle intelligence, while enabling safety and security for on- and off-highway transportation sectors around the world. Additional information about Stoneridge can be found at www.stoneridge.com

Forward-Looking Statements
Statements in this press release contain “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. These statements appear in a number of places in this press release and may include statements regarding the intent, belief or current expectations of the Company, with respect to, among other things, our (i) future product and facility expansion, (ii) strategic focus following the sale of the Control Devices segment, (iii) acquisition strategy, (iv) investments and new product development, (v) growth opportunities related to awarded business, and (vi) operational expectations. Forward-looking statements may be identified by the words “will,” “may,” “should,” “could,” “would,” “designed to,” “believes,” “plans,” “projects,” “intends,” “expects,” “estimates,” “anticipates,” “continue,” and similar words and expressions. The forward-looking statements are subject to risks and uncertainties that could cause actual events or results to differ materially from those expressed in or implied by these statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, among other factors:

the ability of our suppliers to supply us with parts and components at competitive prices on a timely basis, including the impact of potential tariffs and trade considerations on their operations and output;fluctuations in the cost and availability of key materials and components (including semiconductors, printed circuit boards, resin, aluminum, steel and copper) and our ability to offset cost increases through negotiated price increases with or reimbursements from our customers or other cost reduction actions, as necessary;global economic trends, competition and geopolitical risks, including impacts from ongoing or potential global conflicts and any related sanctions and other measures, or an escalation of sanctions, tariffs or other trade tensions between the U.S. and other countries;tariffs specifically in countries where we have significant direct or indirect manufacturing or supply chain exposure and our ability to either mitigate the impact of tariffs or pass any incremental costs to our customers;our ability to achieve cost reductions that offset or exceed customer-mandated selling price reductions;the reduced purchases, loss, financial distress or bankruptcy of a major customer or supplier;the costs and timing of business realignment, facility closures or similar actions;a significant change in commercial, automotive, off-highway or agricultural vehicle production;competitive market conditions and resulting effects on sales and pricing;foreign currency fluctuations and our ability to manage those impacts;customer acceptance of new products;our ability to successfully launch/produce products for awarded business;adverse changes in laws, government regulations or market conditions affecting our products, our suppliers, or our customers’ products;our ability to protect our intellectual property and successfully defend against assertions made against us;liabilities arising from warranty claims, product recall or field actions, product liability and legal proceedings to which we are or may become a party, or the impact of product recall or field actions on our customers;labor disruptions at our facilities, or at any of our significant customers or suppliers;business disruptions due to natural disasters or other disasters outside of our control;the amount of our indebtedness and the restrictive covenants contained in the agreements governing our indebtedness, including our revolving credit facility;capital availability or costs, including changes in interest rates;refinancing risk and access to capital markets and liquidity;the failure to achieve the successful integration of any acquired company or business;risks related to a failure of our information technology systems and networks, and risks associated with current and emerging technology threats and damage from computer viruses, unauthorized access, cyber-attack and other similar disruptions;the items described in Part I, Item 1A (“Risk Factors”) in the Company’s most recent Form 10-K.

The forward-looking statements contained herein represent our estimates only as of the date of this filing and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, except as required by law, we specifically disclaim any obligation to do so, whether to reflect actual results, changes in assumptions, changes in other factors affecting such forward-looking statements or otherwise.

Use of Non-GAAP Financial Information

This press release contains information about the Company’s financial results that is not presented in accordance with accounting principles generally accepted in the United States (“GAAP”). Such non-GAAP financial measures are reconciled to their closest GAAP financial measures at the end of this press release. The provision of these non-GAAP financial measures for 2026 and 2025 is not intended to indicate that Stoneridge is explicitly or implicitly providing projections on those non-GAAP financial measures, and actual results for such measures are likely to vary from those presented. The reconciliations include all information reasonably available to the Company at the date of this press release and the adjustments that management can reasonably estimate.

In evaluating its business, the Company considers and uses net debt as a supplemental measure of its liquidity and the other non-GAAP financial measures as supplemental measures of its operating performance. Management believes the non-GAAP financial measures used in this press release are useful to both management and investors in their analysis of the Company’s financial position and results of operations. In particular, management believes that adjusted gross profit and margin, adjusted operating income (loss) and margin, adjusted income (loss) before tax, adjusted income tax expense (benefit), adjusted net loss from continuing operations, adjusted net income (loss), adjusted EPS, EBITDA, adjusted EBITDA, and net debt are useful measures in assessing the Company’s financial performance by excluding certain items that are not indicative of the Company’s core operating performance or that may obscure trends useful in evaluating the Company’s continuing operating activities. Management also believes that these measures are useful to both management and investors in their analysis of the Company’s results of operations and provide improved comparability between fiscal periods.

Adjusted gross profit and margin, adjusted operating income (loss) and margin, adjusted income (loss) before tax, adjusted income tax expense (benefit), adjusted net income loss from continuing operations, adjusted net income (loss), adjusted EPS, EBITDA, adjusted EBITDA, and net debt should not be considered in isolation or as a substitute for gross profit, operating income (loss), income (loss) before tax, income tax expense (benefit), loss from continuing operations, net income (loss), EPS, debt, cash and cash equivalents, cash provided by operating activities or other income statement or cash flow statement data prepared in accordance with GAAP. Because not all companies calculate non-GAAP financial measures in the same manner, the non-GAAP financial measures presented in this press release may not be comparable to similarly titled measures used by other companies, and the Company’s use of these measures may vary from that of other companies in its industry.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

June 30,
2026

December 31,
2025

(unaudited)

ASSETS

Current assets:

Cash and cash equivalents

$       71,514

$       53,057

Accounts receivable, less reserves of $543 and $325, respectively

135,744

89,019

Inventories, net

112,999

106,422

Prepaid expenses and other current assets

24,025

26,956

Current assets of discontinued operations

86,342

Total current assets

344,282

361,796

Long-term assets:

Property, plant and equipment, net

61,117

62,659

Intangible assets, net

33,077

37,632

Goodwill

36,528

37,590

Operating lease right-of-use asset

8,486

9,570

Investments and other long-term assets, net

23,236

22,167

Long-term assets of discontinued operations

19,702

Total long-term assets

162,444

189,320

Total assets

$      506,726

$      551,116

LIABILITIES AND SHAREHOLDERS’ EQUITY

Accounts payable

$      108,297

$       62,398

Accrued expenses and other current liabilities

73,757

65,132

Current liabilities of discontinued operations

29,955

Total current liabilities

182,054

157,485

Long-term liabilities:

Revolving credit facility

151,089

180,942

Deferred income taxes

8,688

9,972

Operating lease long-term liability

5,776

6,601

Other long-term liabilities

9,994

11,604

Long-term liabilities of discontinued operations

4,733

Total long-term liabilities

175,547

213,852

Preferred Shares, without par value, 5,000 shares authorized, none issued

Common Shares, without par value, 60,000 shares authorized, 28,966 and 28,966
shares issued and 28,524 and 28,018 shares outstanding at June 30, 2026 and
December 31, 2025, respectively, with no stated value

Additional paid-in capital

204,854

219,186

Common Shares held in treasury, 442 and 948 shares at June 30, 2026 and
December 31, 2025, respectively, at cost

(9,649)

(27,457)

Retained earnings

43,957

77,150

Accumulated other comprehensive loss

(90,037)

(89,100)

Total shareholders’ equity

149,125

179,779

Total liabilities and shareholders’ equity

$      506,726

$      551,116

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Three months ended
June 30,

Six months ended
June 30,

(in thousands, except per share data)

2026

2025

2026

2025

Net sales

$      181,384

$      157,541

$      342,231

$      306,598

Costs and expenses:

Cost of goods sold

144,551

121,192

270,442

234,998

Selling, general and administrative

26,061

25,704

58,590

51,569

Design and development

11,960

14,841

23,365

28,533

Operating loss

(1,188)

(4,196)

(10,166)

(8,502)

Interest expense, net

2,404

3,233

6,089

6,475

Equity in (earnings) loss of investee

(222)

(50)

9

(344)

Other (income) expense, net

(649)

2,222

(179)

1,396

Loss before income taxes from continuing operations

(2,721)

(9,601)

(16,085)

(16,029)

Provision for income taxes from continuing operations

2,555

1,542

3,969

3,118

Loss from continuing operations

(5,276)

(11,143)

(20,054)

(19,147)

Discontinued operations:

Loss (gain) from discontinued operations, net of tax

(1,784)

3,322

(2,592)

Loss on disposal, net of tax

9,817

Loss (gain) from discontinued operations

(1,784)

13,139

(2,592)

Net loss

$       (5,276)

$        (9,359)

$      (33,193)

$      (16,555)

Loss per share from continuing operations:

Basic

$         (0.19)

$         (0.40)

$         (0.71)

$         (0.69)

Diluted

$         (0.19)

$         (0.40)

$         (0.71)

$         (0.69)

Loss per share from discontinued operations:

Basic

$            —

$          0.06

$         (0.47)

$          0.09

Diluted

$            —

$          0.06

$         (0.47)

$          0.09

Loss per share from Stoneridge Inc.:

Basic

$         (0.19)

$         (0.34)

$         (1.18)

$         (0.60)

Diluted

$         (0.19)

$         (0.34)

$         (1.18)

$         (0.60)

Weighted-average shares outstanding:

Basic

28,244

27,788

28,071

27,734

Diluted

28,244

27,788

28,071

27,734

Regulation G Non-GAAP Financial Measure Reconciliations

Exhibit 1 – Reconciliation of Adjusted Gross Profit

(USD in millions)

Q2 2025

Q2 2026

Gross Profit

$          36.3

$          36.8

Add: Pre-Tax Business Realignment Costs

Adjusted Gross Profit

$          36.3

$          36.8

Exhibit 2 – Reconciliation of Adjusted Operating Loss

Reconciliation of Adjusted Operating Loss

(USD in millions)

Q2 2025

Q2 2026

Operating Loss

$          (4.2)

$          (1.2)

Add: Pre-Tax Business Realignment Costs

1.4

Add: Pre-Tax Share-Based Compensation Accelerated Vesting

0.3

0.4

Add: Pre-Tax Brazilian Indirect Taxes

(0.3)

Adjusted Operating Loss

$          (2.5)

$          (1.0)

Exhibit 3 – Reconciliation of Q2 Adjusted Tax Rate

Reconciliation of Q2 2026 Adjusted Tax Rate

(USD in millions)

Q2 2026

Tax Rate

Loss Before Tax

$          (2.7)

Add: Pre-Tax Share-Based Compensation Accelerated Vesting

0.4

Add: Pre-Tax Brazilian Indirect Taxes

(0.5)

Adjusted Loss Before Tax

$          (2.8)

Income Tax Expense

2.6

(93.84) %

Add: Tax Impact from Pre-Tax Adjustments

(0.2)

Add: After-Tax Impact of Valuation Allowances, net

Adjusted Income Tax Expense on Adjusted Loss Before Tax

$           2.4

(85.64) %

Exhibit 4 – Reconciliation of Adjusted Net Loss and EPS

Reconciliation of Q2 2026 Adjusted Net Income and EPS

(USD in millions, except EPS)

Q2 2026

Q2 2026 EPS

Net Loss

$          (5.3)

$        (0.19)

Add: After-Tax Share-Based Compensation Accelerated Vesting

0.4

0.02

Add: After-Tax Brazilian Indirect Taxes

(0.3)

(0.01)

Adjusted Net Loss

$          (5.2)

$        (0.18)

Exhibit 5 – Reconciliation of Adjusted EBITDA

Reconciliation of Adjusted EBITDA

(USD in millions)

Q2 2025

Q2 2026

Loss Before Income Taxes from Continuing Operations

$          (9.6)

$          (2.7)

Interest expense, net

3.2

2.4

Depreciation and amortization

5.5

5.6

EBITDA

$          (0.9)

$           5.3

Add: Pre-Tax Business Realignment Costs

1.4

Add: Pre-Tax Share-Based Compensation Accelerated Vesting

0.3

0.4

Add: Pre-Tax Brazilian Indirect Taxes

(0.3)

Adjusted EBITDA

$           0.8

$           5.5

Exhibit 6 – Segment Adjusted Operating Income

Reconciliation of Electronics Adjusted Operating Income

(USD in millions)

Q2 2025

Q2 2026

Electronics Operating Income

$           2.7

$           4.9

Add: Pre-Tax Business Realignment Costs

1.4

Electronics Adjusted Operating Income

$           4.2

$           4.9

Reconciliation of Stoneridge Brazil Adjusted Operating Income

(USD in millions)

Q2 2025

Q2 2026

Stoneridge Brazil Operating Income

$           1.0

$           2.6

Add: Pre-Tax Brazilian Indirect Taxes

(0.3)

Stoneridge Brazil Adjusted Operating Income

$           1.0

$           2.3

Exhibit 7 – Reconciliation of Net Debt

(USD in millions)

Q2 2025

Q2 2026

Total Debt

$        164.4

$        151.1

Cash and Cash Equivalents

46.3

71.5

Net Debt

$        118.1

$          79.6

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/stoneridge-reports-second-quarter-2026-results-302843860.html

SOURCE Stoneridge, Inc.

Continue Reading

Technology

Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

Published

on

By

– First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile –

– First global regulatory approval of obicetrapib marks a defining milestone for NewAmsterdam and Menarini, expanding treatment options for patients with elevated LDL-C –

FLORENCE, Italy, NAARDEN, Netherlands and MIAMI, Sept. 21, 2026 /PRNewswire/ — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, along with partner Menarini Group (“Menarini”), today announced that the European Commission (EC) has granted marketing authorization for Ubeslo® (obicetrapib 10 mg monotherapy) and Evlarco® (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination) for patients with primary hypercholesterolaemia, both heterozygous familial (“HeFH”) and non-familial or mixed dyslipidaemia, marking the first regulatory approval of obicetrapib worldwide.

“The European Commission approval of Ubeslo and Evlarco marks a major milestone for NewAmsterdam as the first regulatory approval of obicetrapib globally, a novel oral therapy, and validates years of work focused on delivering a potential new treatment option for patients who continue to struggle to achieve recommended LDL-C levels despite previously available therapies,” said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma. “This first-in-class approval reflects the strength of the clinical evidence supporting obicetrapib, the dedication of our team and partners, and our commitment to addressing one of the largest unmet needs in cardiovascular medicine. Together with Menarini, we look forward to bringing Ubeslo and Evlarco to patients across Europe and building on this important milestone as we advance our vision of making obicetrapib available to patients around the world.”

The European Commission approval follows the positive opinion adopted by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) and is supported by data from NewAmsterdam’s comprehensive clinical development program evaluating obicetrapib, including the Phase 3 BROADWAY, BROOKLYN and TANDEM trials, which demonstrated statistically significant LDL-C reductions of up to 40% with obicetrapib monotherapy versus placebo and approximately 50% with obicetrapib combined with ezetimibe versus placebo, with a tolerability profile comparable to placebo. NewAmsterdam and Menarini continue to advance the clinical development of obicetrapib through multiple ongoing Phase 3 trials, including PREVAIL, a cardiovascular outcomes trial, as well as REMBRANDT and RUBENS.

“This approval represents an important advancement for patients across Europe who require additional LDL-C lowering despite available therapies,” said Elcin Barker Ergun, Chief Executive Officer of Menarini Group. “We are proud to reach this significant achievement alongside NewAmsterdam and look forward to leveraging our well-established commercial capabilities and deep cardiovascular expertise to bring Ubeslo and Evlarco to healthcare providers and eligible patients throughout Europe.”

Under the parties’ licensing agreement, Menarini holds exclusive commercialization rights for obicetrapib in Europe and is responsible for regulatory interactions and commercialization activities throughout the region. NewAmsterdam is entitled to tiered double-digit percentage royalties ranging from the low double-digits to mid-twenties on net sales in the Menarini Territory and up to an additional €833 million upon the achievement of various clinical, regulatory and commercial milestones.

For full details on the approved indications, contraindications, warnings, and precautions please refer to the Summary of Product Characteristics (SmPC) which will be made available on the European Medicines Agency websites at:
https://www.ema.europa.eu/en/medicines/human/EPAR/ubeslo
https://www.ema.europa.eu/en/medicines/human/EPAR/evlarco 

About Obicetrapib

Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of Major Adverse Cardiovascular Events (“MACE”). The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company.

About Cardiovascular Disease

Cardiovascular disease remains the leading cause of death globally, despite the availability of lipid-lowering therapies (“LLTs”). By 2050 more than 184 million U.S. adults are expected to be affected by CVD and hypertension, including 27 million with coronary heart disease and 19 million with stroke. In the United States from 2019 through 2022, CVD age-adjusted mortality rates increased by 9%, reversing the trend observed since 2010 and undoing nearly a decade of progress. Despite the availability of high-intensity statins and non-statin LLTs, LDL-C target level attainment remains low, contributing to residual cardiovascular risk, and underscoring a significant clinical need for improved therapeutic regimens. Even with 269 million LLT prescriptions written over the last 12 months, 30 million under-treated US adults are not at their risk-based LDL-C goal, of which 13 million have ASCVD. Less than 1 in 4 patients with ASCVD achieve an LDL-C goal of less than 70 mg/dL and only 10% of very high risk ASCVD patients achieve the goal below 55 mg/dL. In addition to the 30 million under-treated U.S. adults, there are 10 million patients diagnosed with elevated LDL-C who are not taking any LLTs including statins. Beyond LDL-C, additional factors are at play, such as lifestyle choices, tobacco use, and obesity, as well as inflammation, thrombosis, triglyceride levels, elevated Lp(a) levels, and type 2 diabetes.

About NewAmsterdam

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company dedicated to build a new standard of care for people living with cardiometabolic disease. The Company is advancing therapies designed to address a significant unmet need for safe, well-tolerated, and convenient treatment options that lower LDL-C while advancing innovation beyond a single marker to better address cardiovascular risk. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose, once-daily CETP inhibitor, alone and as a fixed-dose combination with ezetimibe, in patients at risk of cardiovascular disease with elevated LDL-C. Guided by its mission, the Company challenges convention with courage, translates deep biological insight into meaningful patient impact, and delivers with rigor, precision, and purpose.

About Menarini Group

The Menarini Group, with headquarters in Florence, is present in 140 countries worldwide to date, with $5.5 billion in consolidated turnover and more than 17,000 employees. Menarini’s products are present in the most important treatment areas, including those of cardiometabolic, oncology, gastroenterology, diabetology, pneumology, and anti-inflammatory/analgesic products. Through its commitment to R&D and high-quality manufacturing activities, Menarini continuously contributes to patients’ health worldwide, maintaining the highest quality standards.

Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and are subject to the “safe harbor” provisions created thereunder. All statements that are not historical facts are hereby identified as forwarding-looking statements for this purposes and include, among others, statements relating to: the therapeutic potential of obicetrapib; expected availability of Ubeslo and Evlarco across Europe; the Company’s licensing agreement with Menarini and entitlement to potential future payments thereunder; the continued advancement of clinical development of obicetrapib through multiple ongoing Phase 3 trials; and other statements regarding the Company’s future operations, prospects, objectives, strategies and other future events. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These forward-looking statements are based upon management’s current expectations and assumptions. Actual results or events could differ materially and adversely from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various risks, uncertainties and other factors, including, among others: whether projections regarding clinical outcomes will reflect actual results in clinical use of Ubeslo and Evlarco; risks related to the Company’s ability to achieve its business plans, objectives and milestones, including those related to its licensing agreement with Menarini; challenges inherent to the clinical development and launch of new drug products; risks related to the Company’s reliance on third parties; and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, that are described in greater detail in the sections entitled “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 18, 2026 and in its Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026, as well as in other filings the Company may make with the SEC in the future, which are available at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date of this press release, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of new information, future events, changed circumstances or otherwise, except as otherwise required by law.

BROADWAY (NCT05142722)
BROOKLYN (NCT05425745)
OCEAN NCT04770389
PREVAIL (NCT05202509)
REMBRANDT (NCT06305559)
ROSE NCT04753606
ROSE2 NCT05266586
RUBENS (NCT07219602)
TANDEM (NCT06005597)
TULIP NCT01970215

(Translations: in the event of any discrepancy, the English language version prevails)

 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/menarini-group-and-newamsterdam-pharma-receive-european-commission-approval-for-ubeslo-obicetrapib-monotherapy-and-evlarco-obicetrapib-plus-ezetimibe-fixed-dose-combination-302884871.html

Continue Reading

Technology

Georgia Power furthers partnership with statewide nonprofit to make Georgia State Parks more accessible and enjoyable

Published

on

By

Company joins with Friends of Georgia State Parks for annual volunteer effort on September 26; New $10,000 donation to kickstart “Georgia in Color” initiative for color accessibility glasses

ATLANTA, Sept. 21, 2026 /PRNewswire/ — Georgia Power, the state’s leading electric utility serving customers in all but four Georgia counties, is proud to continue its longstanding partnership with Friends of Georgia State Parks & Historic Sites (Friends) – a nonprofit organization with a mission to serve, support, and celebrate Georgia State Parks & Historic Sites.

This Saturday, September 26, hundreds of Georgia Power volunteers are expected to deploy for Your State Parks Day, an annual event hosted by Friends to clean up, beautify and care for Georgia’s state parks in celebration of National Public Lands Day. Fellow Georgians are also invited to join the volunteer event, or support the program in other ways by donating to Friends or simply sharing their favorite state parks memory. All of the information, including event and registration details by local state park, is available on the Friends of Georgia State Parks & Historic Sites website.

Georgia Power is also donating $10,000 to help kickstart a new fundraising effort by Friends to place free EnChroma color accessibility glasses in all Georgia State Parks for visitor use. For many people with red-green color vision deficiency, the vibrant colors of fall foliage, spring wildflowers, and Georgia’s scenic landscapes may appear less distinct. EnChroma glasses use specialized optical filters designed to enhance color contrast, helping many people distinguish certain colors more easily. Georgia Power’s donation follows a $25,000 donation at the end of 2025 to Friends to develop the program, and previous work with the Aimee Copeland Foundation to place all-terrain Trackchairs in Georgia State Parks for visitor use.

“Georgia’s state parks are a tremendous natural resource and asset for our state, driving travel and tourism for local communities and hosting millions of visitors each year,” said Trey Kilpatrick, senior vice president of External Affairs. “At Georgia Power, we’re committed to making our communities better because we are here. We’re excited to help more visitors enjoy a full experience through the Georgia in Color initiative, and to continue to partner with Friends of Georgia State Parks to protect and care for these special places so they can be enjoyed by Georgians and visitors from around the world for generations to come.”

“Georgia in Color is about helping more visitors fully experience the natural beauty of Georgia’s state parks,” said Damon Kirkpatrick, president and CEO of Friends of Georgia State Parks & Historic Sites. “Georgia Power’s generous investment in this initiative, together with the hands-on service of its volunteers, demonstrates a meaningful commitment to making these treasured places more accessible, welcoming, and enjoyable for everyone.”

Friends is a nonprofit organization with a mission to serve, support, and celebrate Georgia State Parks & Historic Sites. Statewide, Friends works to raise awareness of the economic and intrinsic values of Georgia’s greatest treasures. The organization works with state and community leaders to help make sure that Georgia’s natural and cultural resources are well protected, well maintained and well preserved for generations to come. At the local level, more than 50 chapters work with their respective sites to support individual projects and programs, with thousands of hours of volunteer time donated each year.

To learn more about Friends of Georgia State Parks & Historic Sites, and the organization’s Your State Parks Day program, visit: https://friendsofgastateparks.org/.

About Georgia Power 
Georgia Power is the largest electric subsidiary of Southern Company (NYSE: SO), America’s premier energy company. Value, Reliability, Customer Service and Stewardship are the cornerstones of the company’s promise to 2.8 million customers in all but four of Georgia’s 159 counties. Committed to delivering clean, safe, reliable and affordable energy, Georgia Power maintains a diverse, innovative generation mix that includes nuclear, coal and natural gas, as well as renewables such as solar, hydroelectric and wind. Georgia Power offers rates below the national average, focuses on delivering world-class service to its customers every day and the company is recognized by J.D. Power as an industry leader in customer satisfaction. For more information, visit www.GeorgiaPower.com and connect with the company on Facebook (Facebook.com/GeorgiaPower), X (X.com/GeorgiaPower) and Instagram (Instagram.com/ga_power).

www.georgiapower.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/georgia-power-furthers-partnership-with-statewide-nonprofit-to-make-georgia-state-parks-more-accessible-and-enjoyable-302884857.html

SOURCE Georgia Power

Continue Reading

Technology

HOIN Launches HOP-HQ400 Industrial-Grade, Drop-Resistant and Water-Resistant 4-Inch Portable Thermal Printer

Published

on

By

Dual-Mode Label and Receipt Printing for Demanding Mobile Workflows

SHENZHEN, China, Sept. 21, 2026 /PRNewswire/ — HOIN today announced the launch of the HOP-HQ400, an industrial-grade 4-inch portable thermal printer designed for mobile printing in demanding work environments. Combining dual-mode label and receipt printing with a rugged protective design, flexible connectivity and broad system compatibility, the HOP-HQ400 is built to support logistics, warehousing, delivery, retail and outdoor field operations.

One Printer for Labels and Receipts

The HOP-HQ400 supports both label and receipt printing, allowing users to switch modes according to the task at hand. Receipt printing supports widths of 58mm, 80mm and 104mm, while label printing supports widths from 20mm to 108mm. This flexible media range helps businesses handle different ticket, label and on-site printing requirements with one portable device.

From warehouse identification and logistics operations to courier documents, food-delivery orders, supermarket receipts and outdoor field work, the HOP-HQ400 is designed to simplify mobile printing workflows and reduce the need to switch between devices.

Rugged Protection for Challenging Field Conditions

To help withstand the demands of mobile operations, the HOP-HQ400 features a protective edge-wrapped design and a drop-resistant structure. It supports a 1.5-meter drop resistance rating and an IP56 water-resistance rating, providing added protection against accidental drops and wet working conditions.

“Portable printers get used in ways desktop printers never do,” said Nina Xia, co-founder of HOIN. “The HOP-HQ400 came out of conversations with customers in outdoor delivery and logistics who needed hardware that could handle the environment, not just the print job.”

Fast Output and Flexible Connectivity

The HOP-HQ400 uses an imported Japanese print mechanism and delivers print speeds of up to 100mm/s. A high-power 5200 battery and Type-C interface support mobile use and convenient charging.

The printer offers a range of connectivity options, including USB, Bluetooth, LAN and Wi-Fi. It supports Windows, Android, iOS, Mac and Linux systems, helping customers integrate the device into different terminals and business workflows.

The HOP-HQ400 also supports automatic paper detection and positioning, as well as 1D and 2D barcode printing, helping users improve printing accuracy and on-site processing efficiency.

A 0.96-Inch Display for Easier Setup

A 0.96-inch display enables users to adjust print density, calibrate paper and change interface modes directly on the device. These controls help simplify configuration and reduce operating steps in complex field environments.

Command-Set Compatibility for Customer Integration

For customers that need to integrate the printer into existing software or develop customized applications, the HOP-HQ400 supports TSPL, CPCL and ESC/POS command sets. This compatibility helps customers connect the printer with established systems and adapt it to different application scenarios.

Designed for Multi-Industry Mobile Printing

With dual-mode printing, industrial-grade protection, multiple connectivity options and broad operating-system compatibility, the HOP-HQ400 is designed for applications including:

Logistics and warehousing: on-site labels, cargo identification and work documents.Courier and food delivery: mobile waybills, order receipts and delivery-related information.Supermarkets and retail: receipts and labels in different supported widths.Outdoor and high-altitude operations: on-site printing in mobile, complex or wet environments.

About HOIN

Shenzhen Hoin Electronic Technology Co., Ltd.(HOIN) is a manufacturer of Thermal Printer, Thermal Label Printer, Thermal Transfer Printer, Thermal Barcode Label Printer, Barcode Printer, and portable printing solutions. Established in 2015 and operating from a 10,000㎡ facility in Baoan, Shenzhen, the company serves clients across more than 50 countries in telecom, logistics, retail, and industrial sectors. Certifications include ISO9001:2015, CE, FCC, BSCI, RoHS, CCC, CB, and BIS.

Media Contact:
Person: Nina Xia
Email: nina.xia@hoinprinter.com 
Company: Shenzhen Hoin Electronic Technology Co., Ltd.
Official Website: https://www.hoinprinter.com/ 

View original content to download multimedia:https://www.prnewswire.com/news-releases/hoin-launches-hop-hq400-industrial-grade-drop-resistant-and-water-resistant-4-inch-portable-thermal-printer-302884535.html

SOURCE Shenzhen Hoin Electronic Technology Co., Ltd.

Continue Reading

Trending